Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer

Oncotarget

Volumn 5, Issue 16, 2014, Pages 7065-7080

  Steg, Adam D ^a,b   Burke, Mata R ^a   Amm, Hope M ^a   Katre, Ashwini A ^a   Dobbin, Zachary C ^a   Jeong, Dae Hoon ^c   Landen, Charles N ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SAMFORD UNIVERSITY   (United States)

^c Inje University   (South Korea)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bortezomib; Hedgehog; LDE225; Ovarian cancer; Paclitaxel; Proteasome

Indexed keywords

ALPHA TUBULIN; BORTEZOMIB; GAMMA SECRETASE INHIBITOR; JAGGED1; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; PACLITAXEL; PROPIDIUM IODIDE; PROTEASOME; PROTEIN PATCHED 1; PROTEIN PATCHED 2; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TAXANE DERIVATIVE; TETRAZOLIUM; TRANSCRIPTION FACTOR GLI1; UBIQUITIN; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; BORONIC ACID DERIVATIVE; BRIDGED COMPOUND; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TAXANE; TAXOID;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL VIABILITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; M PHASE CELL CYCLE CHECKPOINT; MEMBRANE STABILIZATION; MICROTUBULE; MOLECULAR INTERACTION; OVARY CANCER; PROTEIN ACETYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIPHENYL COMPOUNDS; BORONIC ACIDS; BORTEZOMIB; BRIDGED COMPOUNDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HEDGEHOG PROTEINS; HUMANS; OVARIAN NEOPLASMS; PROTEASOME INHIBITORS; PYRAZINES; PYRIDINES; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84907067520     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2295     Document Type: Article

References (48)

1. Bhoola S and Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006; 107(6):1399-1410.
2. Wang Z, Li Y, Banerjee S and Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer letters. 2009; 279(1):8-12.
3. Pasca di Magliano M and Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nature reviews Cancer. 2003; 3(12):903-911.
4. Theunissen JW and de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer research. 2009; 69(15):6007-6010.
5. Hopfer O, Zwahlen D, Fey MF and Aebi S. The Notch pathway in ovarian carcinomas and adenomas. British journal of cancer. 2005; 93(6):709-718.
6. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih Ie M and Wang TL. Notch3 gene amplification in ovarian cancer. Cancer research. 2006; 66(12):6312-6318.
7. Choi JH, Park JT, Davidson B, Morin PJ, Shih Ie M and Wang TL. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer research. 2008; 68(14):5716-5723.
8. Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY and An HJ. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer science. 2010; 101(9):1977-1983.
9. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T and Konishi I. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer science. 2007; 98(1):68-76.
10. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V and Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(23):7659-7666.
11. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY and Cheung AN. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis. 2009; 30(1):131-140.
12. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer research. 2008; 68(11):4311-4320.
13. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M and Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. The American journal of pathology. 2010; 177(3):1087-1094.
14. Sims-Mourtada J, Izzo JG, Ajani J and Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007; 26(38):5674-5679.
15. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F and Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene. 2011; 30(49):4874-4886.
16. Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD and Landen CN. Smoothened antagonists reverse taxane resistance in ovarian cancer. Molecular cancer therapeutics. 2012; 11(7):1587-1597.
17. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Developmental cell. 2009; 16(5):633-647.
18. Metcalfe C and de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer research. 2011; 71(15):5057-5061.
19. Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009; 326(5952):572-574.
20. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Science translational medicine. 2010; 2(51):51ra70.
21. Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K, Sutherlin D, Scales SJ, Gould SE, Yauch RL and de Sauvage FJ. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer research. 2011; 71(2):435-444.
22. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP and Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006; 107(12):4907-4916.
23. Adams J. The proteasome: a suitable antineoplastic target. Nature reviews Cancer. 2004; 4(5):349-360.
24. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Current opinion in chemical biology. 2002; 6(4):493-500.
25. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A and Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012; 120(5):947-959.
26. Reddy N and Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21(9):1756-1764.
27. Hideshima T, Richardson PG and Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Molecular cancer therapeutics. 2011; 10(11):2034-2042.
28. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(16):4094-4104.
29. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J and Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(25):5943-5949.
30. Ramirez PT, Landen CN, Jr., Coleman RL, Milam MR, Levenback C, Johnston TA and Gershenson DM. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic oncology. 2008; 108(1):68-71.
31. Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ and Riordan W. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology. 2009; 115(2):215-220.
32. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK and Landen CN. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(17):5674-5685.
33. Han J, Ma I, Hendzel MJ and Allalunis-Turner J. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast cancer research: BCR. 2009; 11(4):R57.
34. Monticone M, Biollo E, Fabiano A, Fabbi M, Daga A, Romeo F, Maffei M, Melotti A, Giaretti W, Corte G and Castagnola P. z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Molecular cancer research: MCR. 2009; 7(11):1822-1834.
35. Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen IM, Harvey RC, Hunger SP, Ness SA, Winter SS and Wilson BS. GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2011; 25(7):1135-1146.
36. Hooper JE and Scott MP. Communicating with Hedgehogs. Nature reviews. 2005; 6(4):306-317.
37. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C and Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle. 2008; 7(7):940-949.
38. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012; 119(11):2579-2589.
39. Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB and LaRusso NF. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer research. 2013; 73(7):2259-2270.
40. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B and Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. Journal of the American Chemical Society. 2010; 132(31):10842-10846.
41. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(3):869-881.
42. Tsubuki S, Kawasaki H, Saito Y, Miyashita N, Inomata M and Kawashima S. Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochemical and biophysical research communications. 1993; 196(3):1195-1201.
43. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature. 2002; 417(6887):455-458.
44. Lowe J, Li H, Downing KH and Nogales E. Refined structure of alpha beta-tubulin at 3.5 A resolution. Journal of molecular biology. 2001; 313(5):1045-1057.
45. Duan Z, Feller AJ, Toh HC, Makastorsis T and Seiden MV. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene. 1999; 229(1-2):75-81.
46. Landen CN, Jr., Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006; 98(21):1558-1570.
47. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE and Johnson MR. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn. 2006; 8(1):76-83.
48. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation. 1984; 22:27-55.